Every 10-Q that Biomea Fusion, Inc. (BMEA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BMEA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMEA filings page.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, reported Q2 2026 results showing continued losses but lower spending. For the three months ended June 30, 2026, the company recorded a net loss of $8.3 million compared with $20.7 million a year earlier, with no product revenue.
Operating expenses fell to $12.8 million, driven by reduced research and development spending of $9.1 million (down from $16.6 million) and general and administrative costs of $3.6 million (down from $4.7 million), reflecting lower headcount and facilities costs. Net cash used in operating activities for the first half of 2026 was $21.7 million.
Liquidity remains tight. As of June 30, 2026, cash, cash equivalents and restricted cash totaled $35.2 million, and management expects this to fund operations only into the second quarter of 2027. The company states there is substantial doubt about its ability to continue as a going concern without additional financing. Biomea continues to advance icovamenib in Phase II trials for type 2 diabetes and BMF-650 in a Phase I obesity study while seeking to partner its oncology asset BMF-500.
Biomea Fusion, Inc. reported a net loss of $12.4 million for the quarter ended March 31, 2026, narrower than the $29.3 million loss a year earlier, as it sharply reduced research and development and administrative spending while remaining pre‑revenue.
Quarter-end cash, cash equivalents and restricted cash totaled $45.1 million, with management stating this is expected to fund operations only into the first quarter of 2027, creating substantial doubt about the company’s ability to continue as a going concern without additional financing. The company focuses on clinical-stage diabetes and obesity programs, including Phase II trials of icovamenib in type 2 diabetes and a Phase I trial of BMF-650 in obesity, and ended the quarter with 72.3 million common shares outstanding and a $461.5 million accumulated deficit.
Biomea Fusion, Inc. (BMEA) filed its Q3 2025 report, highlighting reduced operating spend and liquidity pressure. The company reported a Q3 net loss of $16.4 million and basic/diluted loss per share of $0.27. Operating expenses fell to $20.8 million, driven by lower research and development costs, while interest and other income was $4.4 million.
Cash, cash equivalents and restricted cash were $47.0 million as of September 30, 2025. The filing states there is substantial doubt about the company’s ability to continue as a going concern, absent additional financing. A $2.2 million non‑cash impairment was recorded after ceasing laboratory use for R&D. A warrant liability of $17.9 million reflects the fair value of common warrants issued in June 2025.
To bolster liquidity, the company completed public offerings in June and on October 6, 2025, with the October transaction generating approximately $25.0 million in gross proceeds. Shares outstanding were 59,508,518 as of September 30, 2025 and 70,703,639 as of October 31, 2025. Clinical programs continue, including Phase II trials of icovamenib in diabetes and the IND‑cleared BMF‑650 with an ongoing Phase I trial.